Currently, patients with schizophrenia are usually considered refractory to
treatment if they continue to be floridly symptomatic despite receiving tr
eatment with conventional antipsychotic agents. Attempts to improve their r
esponse by increasing the dosage, adding supplementary drugs, or switching
to agents of another class have not been very successful, and may increase
side-effects. Clozapine can be effective, but it is a difficult drug to adm
inister and has therefore been reserved for patients who are doing poorly.
With the recent introduction of newer, safer antipsychotic agents, however,
even patients who have milder refractory symptoms that persist after treat
ment with conventional antipsychotics can now be treated.